Histoculture drug response assay on non-small cell lung cancer

T. Yoshimasu, S. Oura, S. Maebeya, H. Tanino, T. Bessho, J. Arimoto, T. Sakurai, K. Matsuyama, Y. Naito, Toshiharu Furukawa, T. Yano, T. Suzuma, I. Hirai

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We examined the chemosensitivity of non-small cell lung cancer (NSCLC) tissues to CDDP, 5-FU, ADM, MMC, ETP and SN38 using histoculture drug response assay (HDRA). One-hundred and thirty surgical specimens from NSCLC patients who were not given preoperative chemotherapy were used. The inhibition indexes of CDDP, 5-FU, MMC, ADM, ETP and SN38 were 39.1 +/- 18.2%, 48.0 +/- 19.7%, 63.3 +/- 17.7%, 47.6 +/- 22.0%, 36.9 +/- 21.1%, and 37.9 +/- 25.2%, respectively. Inhibition indexes were above the cutoff level, i.e., 'judged sensitive,' in 40 cases (31.3%) for CDDP, 34 cases (27.4%) for 5-FU, 54 cases (44.3%) for MMC, 36 cases (33.0%) for ADM, 29 cases (29.8%) for ETP, and 34 cases (37.4%) for SN38, respectively. In almost one-third of patients, the inhibition indexes of all drugs were under cutoff levels. Correlations between in vitro chemosensitivity data and patient responses to chemotherapy were obtained from 16 evaluable patients, and a 44.4% true positive rate and a 100% true negative rate were observed. Our results with HDRA for NSCLC showed a high incidence of intrinsic multidrug resistance. HDRA may help doctors to avoid non-effective chemotherapy for NSCLC patients.

Original languageEnglish
Pages (from-to)717-722
Number of pages6
JournalJapanese Journal of Cancer and Chemotherapy
Volume27
Issue number5
Publication statusPublished - 2000 May
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Fluorouracil
Pharmaceutical Preparations
Drug Therapy
Multiple Drug Resistance
Incidence

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Yoshimasu, T., Oura, S., Maebeya, S., Tanino, H., Bessho, T., Arimoto, J., ... Hirai, I. (2000). Histoculture drug response assay on non-small cell lung cancer. Japanese Journal of Cancer and Chemotherapy, 27(5), 717-722.

Histoculture drug response assay on non-small cell lung cancer. / Yoshimasu, T.; Oura, S.; Maebeya, S.; Tanino, H.; Bessho, T.; Arimoto, J.; Sakurai, T.; Matsuyama, K.; Naito, Y.; Furukawa, Toshiharu; Yano, T.; Suzuma, T.; Hirai, I.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 27, No. 5, 05.2000, p. 717-722.

Research output: Contribution to journalArticle

Yoshimasu, T, Oura, S, Maebeya, S, Tanino, H, Bessho, T, Arimoto, J, Sakurai, T, Matsuyama, K, Naito, Y, Furukawa, T, Yano, T, Suzuma, T & Hirai, I 2000, 'Histoculture drug response assay on non-small cell lung cancer', Japanese Journal of Cancer and Chemotherapy, vol. 27, no. 5, pp. 717-722.
Yoshimasu T, Oura S, Maebeya S, Tanino H, Bessho T, Arimoto J et al. Histoculture drug response assay on non-small cell lung cancer. Japanese Journal of Cancer and Chemotherapy. 2000 May;27(5):717-722.
Yoshimasu, T. ; Oura, S. ; Maebeya, S. ; Tanino, H. ; Bessho, T. ; Arimoto, J. ; Sakurai, T. ; Matsuyama, K. ; Naito, Y. ; Furukawa, Toshiharu ; Yano, T. ; Suzuma, T. ; Hirai, I. / Histoculture drug response assay on non-small cell lung cancer. In: Japanese Journal of Cancer and Chemotherapy. 2000 ; Vol. 27, No. 5. pp. 717-722.
@article{f048b3c39ce04676be8776f408c05e9c,
title = "Histoculture drug response assay on non-small cell lung cancer",
abstract = "We examined the chemosensitivity of non-small cell lung cancer (NSCLC) tissues to CDDP, 5-FU, ADM, MMC, ETP and SN38 using histoculture drug response assay (HDRA). One-hundred and thirty surgical specimens from NSCLC patients who were not given preoperative chemotherapy were used. The inhibition indexes of CDDP, 5-FU, MMC, ADM, ETP and SN38 were 39.1 +/- 18.2{\%}, 48.0 +/- 19.7{\%}, 63.3 +/- 17.7{\%}, 47.6 +/- 22.0{\%}, 36.9 +/- 21.1{\%}, and 37.9 +/- 25.2{\%}, respectively. Inhibition indexes were above the cutoff level, i.e., 'judged sensitive,' in 40 cases (31.3{\%}) for CDDP, 34 cases (27.4{\%}) for 5-FU, 54 cases (44.3{\%}) for MMC, 36 cases (33.0{\%}) for ADM, 29 cases (29.8{\%}) for ETP, and 34 cases (37.4{\%}) for SN38, respectively. In almost one-third of patients, the inhibition indexes of all drugs were under cutoff levels. Correlations between in vitro chemosensitivity data and patient responses to chemotherapy were obtained from 16 evaluable patients, and a 44.4{\%} true positive rate and a 100{\%} true negative rate were observed. Our results with HDRA for NSCLC showed a high incidence of intrinsic multidrug resistance. HDRA may help doctors to avoid non-effective chemotherapy for NSCLC patients.",
author = "T. Yoshimasu and S. Oura and S. Maebeya and H. Tanino and T. Bessho and J. Arimoto and T. Sakurai and K. Matsuyama and Y. Naito and Toshiharu Furukawa and T. Yano and T. Suzuma and I. Hirai",
year = "2000",
month = "5",
language = "English",
volume = "27",
pages = "717--722",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "5",

}

TY - JOUR

T1 - Histoculture drug response assay on non-small cell lung cancer

AU - Yoshimasu, T.

AU - Oura, S.

AU - Maebeya, S.

AU - Tanino, H.

AU - Bessho, T.

AU - Arimoto, J.

AU - Sakurai, T.

AU - Matsuyama, K.

AU - Naito, Y.

AU - Furukawa, Toshiharu

AU - Yano, T.

AU - Suzuma, T.

AU - Hirai, I.

PY - 2000/5

Y1 - 2000/5

N2 - We examined the chemosensitivity of non-small cell lung cancer (NSCLC) tissues to CDDP, 5-FU, ADM, MMC, ETP and SN38 using histoculture drug response assay (HDRA). One-hundred and thirty surgical specimens from NSCLC patients who were not given preoperative chemotherapy were used. The inhibition indexes of CDDP, 5-FU, MMC, ADM, ETP and SN38 were 39.1 +/- 18.2%, 48.0 +/- 19.7%, 63.3 +/- 17.7%, 47.6 +/- 22.0%, 36.9 +/- 21.1%, and 37.9 +/- 25.2%, respectively. Inhibition indexes were above the cutoff level, i.e., 'judged sensitive,' in 40 cases (31.3%) for CDDP, 34 cases (27.4%) for 5-FU, 54 cases (44.3%) for MMC, 36 cases (33.0%) for ADM, 29 cases (29.8%) for ETP, and 34 cases (37.4%) for SN38, respectively. In almost one-third of patients, the inhibition indexes of all drugs were under cutoff levels. Correlations between in vitro chemosensitivity data and patient responses to chemotherapy were obtained from 16 evaluable patients, and a 44.4% true positive rate and a 100% true negative rate were observed. Our results with HDRA for NSCLC showed a high incidence of intrinsic multidrug resistance. HDRA may help doctors to avoid non-effective chemotherapy for NSCLC patients.

AB - We examined the chemosensitivity of non-small cell lung cancer (NSCLC) tissues to CDDP, 5-FU, ADM, MMC, ETP and SN38 using histoculture drug response assay (HDRA). One-hundred and thirty surgical specimens from NSCLC patients who were not given preoperative chemotherapy were used. The inhibition indexes of CDDP, 5-FU, MMC, ADM, ETP and SN38 were 39.1 +/- 18.2%, 48.0 +/- 19.7%, 63.3 +/- 17.7%, 47.6 +/- 22.0%, 36.9 +/- 21.1%, and 37.9 +/- 25.2%, respectively. Inhibition indexes were above the cutoff level, i.e., 'judged sensitive,' in 40 cases (31.3%) for CDDP, 34 cases (27.4%) for 5-FU, 54 cases (44.3%) for MMC, 36 cases (33.0%) for ADM, 29 cases (29.8%) for ETP, and 34 cases (37.4%) for SN38, respectively. In almost one-third of patients, the inhibition indexes of all drugs were under cutoff levels. Correlations between in vitro chemosensitivity data and patient responses to chemotherapy were obtained from 16 evaluable patients, and a 44.4% true positive rate and a 100% true negative rate were observed. Our results with HDRA for NSCLC showed a high incidence of intrinsic multidrug resistance. HDRA may help doctors to avoid non-effective chemotherapy for NSCLC patients.

UR - http://www.scopus.com/inward/record.url?scp=0034183511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034183511&partnerID=8YFLogxK

M3 - Article

C2 - 10832440

AN - SCOPUS:0034183511

VL - 27

SP - 717

EP - 722

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 5

ER -